Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
AcuCort announces today that the nomination committee for the 2023 annual general meeting has been appointed and consists of the company's two largest owners.
- Sarah Fredriksson, appointed by AQILION AB
- Thomas Nestenius, appointed by Zoya Invest AB
The annual general meeting will be held on 4 May 2023 in Lund. The nomination committee's proposal will be presented in the notice to the annual general meeting and on the company's website.
For more information, please contact:
Ebba Fåhraeus, chairman of the board, telephone; 073 400 04 33,ebba@smileincubator.life
The information was submitted for publication, through the agency of the contact person above, on February 13, 2023.
About AcuCort AB (publ)
AcuCort AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark and Norway. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.